COMMUNIQUÉS West-GlobeNewswire

Natural Alternatives International, Inc. Announces 2025 Q3 and YTD Results
14/05/2025
CARLSBAD, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer, and marketer of customized nutritional supplements, today announced [...]
Glucotrack Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
14/05/2025
On track to implant first patients in long-term, multicenter feasibility study of the fully implantable continuous blood glucose monitor (CBGM) system in Australia in Q3 2025 Investigational Device Exemption (IDE) [...]
Precipio Announces its Q1-2025 Financial Results
14/05/2025
Conference call to follow tomorrow, May 15 at 5 PM EST NEW HAVEN, Conn., May 14, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , filed its 10-Q report today. The following [...]
Updated: Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences
14/05/2025
Correction: Time of BofA Conference SALT LAKE CITY, May 14, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that [...]
Profound Medical Annual General and Special Meeting of Shareholders Voting Results
14/05/2025
TORONTO, May 14, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the voting results from its Annual General and Special Meeting of [...]
SS Innovations Reports First Quarter 2025 Financial Results
14/05/2025
Record Quarterly Revenue of $5.1 Million Driven by Higher SSi Mantra 3 Unit Sales On Track for July 2025 De Novo Application to the FDA for SSi Mantra 3 FORT LAUDERDALE, Fla., May 14, 2025 (GLOBE NEWSWIRE) -- SS [...]
Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report
14/05/2025
NOVATO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) released its 2024 Impact Report today, which covers the company’s approach to corporate responsibility. The report [...]
Jasper Therapeutics to Present at Upcoming Investor Conferences
14/05/2025
REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting [...]
STERIS Announces Financial Results for Fiscal 2025 Fourth Quarter and Full Year
14/05/2025
Full year fiscal 2025 revenue from continuing operations increased 6%; constant currency organic revenue growth was 6% Full year fiscal 2025 as reported diluted EPS from continuing operations increased to $6.16; [...]
Eton Pharmaceuticals to Participate at Upcoming Investor Conferences
14/05/2025
DEER PARK, Ill., May 14, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare [...]
Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights
14/05/2025
Bolstered management team with hires of Chief Executive Officer and Chief Medical Officer with deep biopharmaceutical experience Announced selection of IL15-superagonist as first payload to be delivered into tumors with [...]
Catheter Precision, Inc. Announces First Quarter 2025 Update and Financial Results
14/05/2025
FORT MILL, S.C., May 14, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial [...]
FibroBiologics Reports First Quarter 2025 Financial Results and Provides Corporate Update
14/05/2025
Preparations for Phase 1/2 clinical trial in Australia utilizing fibroblast-based spheroids product candidate, CYWC628, to treat diabetic foot ulcers are proceeding with plans to initiate in the third quarter of 2025 [...]
Edesa Biotech Reports Fiscal 2nd Quarter 2025 Results
14/05/2025
TORONTO, May 14, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported [...]
Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
14/05/2025
Continued operational excellence leading to acceleration of multiple timelines: ORKA-001, targeting IL-23p19, Phase 1 trial dosing complete, with data expected in 3Q 2025 ORKA-001 Phase 2a initiation expected in 2H 2025 [...]
X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress
14/05/2025
Meaningful and durable increases in functional neutrophils observed over 6-month trial with oral once-daily mavorixafor Majority of physicians and chronic neutropenia participants chose to significantly reduce G-CSF [...]
GENFIT: Publication of the 2025 Extra-Financial Performance Report (fiscal year 2024)
14/05/2025
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 14, 2025- GENFIT (Nasdaq and Euronext: GNFT) , a biopharmaceutical company dedicated to improving the lives of patients with rare and [...]
GENFIT : Publication du rapport de performance extra-financière 2025 (exercice 2024)
14/05/2025
Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 14 mai 2025 – GENFIT (Nasdaq et Euronext : GNFT) , société biopharmaceutique engagée dans l’amélioration de la vie des patients atteints de [...]
Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights
14/05/2025
Phase 3 HERO trial of ARD-101 for the treatment of hyperphagia associated with Prader-Willi Syndrome (PWS); data readout expected in early 2026 $151.3 million in cash, cash equivalents, and short-term investments [...]

Pages